Clinical trials: Hepatic
Normal Non-fluency
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
Within the past 20 years, there has been a striking increase in the incidence of obesity 1;2, type 2 diabetes mellitus (T2DM) 3-5, and cardiovascular diseases (CVD) in the schizophrenic population 6-8 .
- Trial name
- NCT02447835
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Michael Rickels
Infection, Human Immunodeficiency Virus
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.
- Trial name
- NCT02467335
- Testing
- BMS-663068
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
This is a study of experimental medication BMS-986036 given to healthy participants.
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03445208
- Testing
- BMS-986036
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatic Impairment
Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants
This is a study to compare the pharmacokinetic profile of teduglutide in healthy participants with normal hepatic function with participants who have moderate hepatic impairment.
- Trial name
- NCT00819468
- Testing
- Teduglutide
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shire
Health Technology
MyChart Proxy Outreach to Parents (MyPOP)
The goal of this randomized controlled trial is to assess the extent to which different modes of contacting parents who have not yet enabled to access to their children's medical records will result in greater proxy access.
- Trial name
- MyPOP (NCT05989308)
- Testing
- Email, Text, Patient Portal Message
- Where
- 4 sites in United States
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- Yale University
Oncology
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate)…
- Trial name
- NCT02521376
- Testing
- Entospletinib
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatic Insufficiency
Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease
This study aims to investigate whether liver patients may tolerate alitretinoin by comparing metabolism in 8 such patients with the metabolism in 8 healthy controls
- Trial name
- NCT01261923
- Testing
- Alitretinoin
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Generalized Anxiety Disorder
Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function
This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.
- Trial name
- NCT07457190
- Testing
- Buagafuran
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Pulmonary Embolism, Venous Thrombosis
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
Observational. Retrospective cohort.
- Conditions
- Pulmonary Embolism, Venous Thrombosis, Portal Thrombosis
- Trial name
- NCT02597218
- Where
- Argentina
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Hepatic Impairment, Hepatic Insufficiency
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.
- Conditions
- Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects
- Trial name
- NCT03968848
- Testing
- acalabrutinib
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Acerta Pharma BV
HIV Infections
A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers
This will be a Phase 1, open-label, parallel group, two-part, single-dose adaptive study in adults with moderate and mild (if needed) hepatic impairment and matched, healthy control subjects with normal hepatic function.
- Trial name
- NCT02354950
- Testing
- GSK1265744 30mg
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Asthma
A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.
In relation to their severity, hepatic diseases can significantly modify drug absorption and disposition and consequently can interfere with drug efficacy and/or produce toxicity.
- Trial name
- NCT01266941
- Testing
- Inhaled FF 200mcg/GW642444M 25mcg
- Where
- 3 sites in Czechia, Slovakia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatic Impairment, Healthy Adult Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment
The goal of this study is to understand how the body processes sonrotoclax in adults with serious liver problems compared to adults with normal liver function.
- Trial name
- NCT07855991
- Testing
- Sonrotoclax
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
PK of FG-4592, Hepatic Insufficiency
A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function
The effect of moderately diminished liver function on the exposure, safety and tolerability of a single dose of FG-4592 is studied in male and female subjects.
- Conditions
- PK of FG-4592, Hepatic Insufficiency, Healthy Subjects
- Trial name
- NCT02161224
- Testing
- FG-4592
- Where
- Bulgaria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.
- Trial name
- NCT06846528
- Testing
- AZD2389, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hepatic Insufficiency
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
This study is open to people with and without liver problems. People can join the study if they are 18 to 79 years of age and have a body mass index (BMI) between 18.5 and 35 kg/m2.
- Trial name
- NCT05731895
- Testing
- Iclepertin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatic Impairment
A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment
The primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (PK) of BMS-986263
- Trial name
- NCT04225936
- Testing
- BMS-986263
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
End Stage Renal Disease, End Stage Liver Disease
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with…
- Trial name
- NCT03803423
- Testing
- The Donor App
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans
The purpose of study is to examine whether raised blood glucose enhances lipid particle production independent of effects on gastric emptying and pancreatic/ gastrointestinal hormone production.
- Trial name
- NCT02607839
- Testing
- glucose or normal saline
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Pharmacokinetics, Hepatic Impairment
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
The goal of this clinical trial to learn how MDMA is processed in people with abnormal liver function. The main questions it aims to answer are: Do people with abnormal liver function experience greater absorption of MDMA? Does…
- Trial name
- NCT03606538
- Testing
- Midomafetamine HCl
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals